Risk of heart failure and edema associated with the use of pregabalin: a systematic review
Open Access
- 4 May 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Systematic Reviews
- Vol. 2 (1), 25
- https://doi.org/10.1186/2046-4053-2-25
Abstract
Pregabalin is used in the treatment of postherpetic neuralgia, diabetic neuropathic pain, partial seizures, anxiety disorders and fibromyalgia. Recognized adverse effects associated with its use include cognitive impairment, somnolence and dizziness. Heart failure associated with pregabalin has been described, however the strength of this association has not been well characterized. To examine this further, we will conduct a systematic review of the risk of heart failure and edema associated with use of pregabalin.Keywords
This publication has 18 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trialsEpilepsia, 2011
- A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and GabapentinClinical Pharmacokinetics, 2010
- Cognitive effects of pregabalin in healthy volunteersNeurology, 2010
- Possible heart failure exacerbation associated with pregabalin: case discussion and literature reviewJournal of Cardiovascular Medicine, 2008
- Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting BiasPLOS ONE, 2008
- Decompensation of chronic heart failure associated with pregabalin in a 73‐year‐old patient with postherpetic neuralgia: a case reportBritish Journal of Clinical Pharmacology, 2008
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986